Loading...
Please wait, while we are loading the content...
Similar Documents
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Bernard-Marty, Chantal Mano, Masayuki Paesmans, Mariane Accettura, Caterina Munoz-Bermeo, R. Richard, Taylor J. Kleiber, Kai Cardoso, Fatima Lobelle, Jean Pierre Larsimont, Denis Piccart, Martine J. Leo, Angelo Di |
| Copyright Year | 2003 |
| Abstract | BACKGROUND Alkylating agents and topoisomerase-II inhibitors have been associated with the occurrence of secondary leukemias and myelodysplastic syndromes in breast cancer patients treated with adjuvant chemotherapy. Conversely, data on the occurrence of second solid malignancies in this setting are scarce. PATIENTS AND METHODS This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer. RESULTS At a median follow-up of 73 months, the following 8-year actuarial rates of second solid primaries were observed: CMF 5.5% [95% confidence interval (CI) 1.5% to 9.5%], EC 4.1% (95% CI 0.1% to 8.1%), and HEC 7.2% (95% CI 3.2% to 11.2%) (P = 0.79 by log rank test). Three secondary acute myeloid leukemias (AML) were reported, all in the HEC arm (incidence = 1.2%, 95% CI 0.0% to 2.5%), which by a three arm comparison allows us to conclude that HEC is statistically different (borderline significance) from CMF and EC (P = 0.05). CONCLUSIONS HEC, as delivered in this trial, cannot be recommended in clinical practice because of the lack of superiority over classic CMF and because of the increased risk of AML observed in this arm. Prolongation of conventional anthracycline-based treatment beyond the current standard of four to six cycles is not recommended in clinical practice. |
| Starting Page | 1 |
| Ending Page | 5 |
| Page Count | 5 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://watermark.silverchair.com/mdg204.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAacwggGjBgkqhkiG9w0BBwagggGUMIIBkAIBADCCAYkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMHStoPyFory5FRbDrAgEQgIIBWrYjo6B9mgp2U-jwjAY-J5jH_TVswmqmTfstu0pL5t8_X5UvEgqWaP_Ik2uN5kMbffvwBpsPngGx8DMEfdg2riYzMeUYzT-RLHXdxodtkFzqbennpS-WzloFKAsO_SDFjXDt7PHcmsuU1Nx5PXijlq2QRLsz7Z2qiW_StW9KvtqM-EcML4RvtYzNA0-m89zDlH4pDub4g0sijCPsENGOAKGSACKnOaxxPEVq2MAJrJ5MV2Vd2dAIzRgvMomuq0njtUlHJPN2HFprlreIGtfGtWZAw4Cmz40jhCbh631M2-hQ9SAASmWZYbqUMgbKPcWWki8x-CYqar5Xuw-iBOUU9EMG8LEaDjr6-1nkY8e0xjzF7Vz4XRgrkLtLttspBawzhBK4bNj8WDc0uOsHwpxgzZHAbxduja_5JHNZrWHhkRrAibcOd7FH4M-RCmRwFIymNABE3pKAmVnMFo0 |
| PubMed reference number | 12702521v1 |
| Volume Number | 14 |
| Issue Number | 5 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Alkylating Agents Anatomic Node Anthracyclines Chemotherapy, Adjuvant Confidence Intervals Cyclophosphamide Fluorouracil Follow-Up Report Leukemia, Myelocytic, Acute MYELODYSPLASTIC SYNDROME Mammary Neoplasms Methotrexate NDC80 gene Neoplasms, Second Primary Patients Pharmaceutical Adjuvants cyclophosphamide/fluorouracil/methotrexate protocol secondary acute myeloid leukemia |
| Content Type | Text |
| Resource Type | Article |
